ClinicalTrials.gg
RecruitingNCT06526923SAAVeUpdated Nov 25, 2024

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

A Phase 1/2 interventional study of SP-101 and doxorubicin Cohort 1 and SP-101 and doxorubicin Cohort 2 in Cystic Fibrosis, sponsored by Spirovant Sciences, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Spirovant Sciences, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
403rd of 517
15 · median 36
Started
2024
with 29 others
Phase 1/2
32 of 717
1 open now
Primary completion
2026-12
later than 27 of 108 live
Registered
674th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 403rd largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 32 in phase 1/2, reaches primary completion later than 27 of the 108 other live ones, and was the 674th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

Read the detailed description

This multi-center study is a first-in-human, single ascending dose, Phase 1/2 trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of various dose levels in people with CF who are ineligible or intolerant to CFTR modulator therapy.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • gene therapy
  • SP-101
  • AAV
  • doxorubicin
  • inhaled
  • augmenter
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, age 18 to 65 years at Screening Visit, inclusive
  2. Diagnosis of CF
  3. ppFEV1 value between 50-100% (inclusive)
  4. Resting oxygen saturation ≥94% on room air by pulse oximetry 5 . Clinically stable CF disease as assessed by the Investigator and not requiring any new class of interventional treatment within the last 3 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  1. Any change in established pulmonary treatment (including antibiotics) within 28 days prior to Screening Visit. However, inhaled beta-agonists can be included within 2 weeks prior to Screening Visit.
  2. episode of hemoptysis (>50 mL or ¼ cup or 10 teaspoons per day) within 12 weeks prior to dosing with study drug on Day 1
  3. Lung infection with Mycobacterium abscessus associated with a more rapid decline in pulmonary status
  4. Currently receiving treatment for active lung infection with Burkholderia cenocepacia or Burkholderia dolosa
  5. History of solid organ or hematological transplantation
  6. History of clinically significant cirrhosis with or without portal hypertension
  7. History of pulmonary hypertension
  8. History of cardiotoxicity, a history of known coronary artery disease, and/or existing cardiomyopathy
  9. Current active fungal infection (not just a positive culture), acute blood, lung, or bladder infection, clinically significant hepatic or renal dysfunction, and/or viral infection (including or hepatitis virus B or C) requiring the initiation of new therapy within 30 days prior to Screening
  10. History of allergic bronchopulmonary aspergillosis (ABPA)
  11. Uncontrolled diabetes mellitus, as evidenced by >9% at Screening
  12. Clinically significant laboratory abnormalities at Screening
  13. Subjects with any medical condition or abnormal laboratory result that, in the opinion of the Investigator, will interfere with the safe completion of the study
  14. Subjects who received any products within 30 days (or 5 therapeutic half-lives, whichever is longer) prior to Screening
  15. Subjects who have previously received any gene therapy agent
  16. Subjects with known sensitivity to SP-101, doxorubicin or its
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Single inhalational administration of SP-101 and doxorubicin Dose 1

    Combination Product: SP-101 and doxorubicin Cohort 1

  • Experimental
    Cohort 2

    Single inhalational administration of SP-101 and doxorubicin Dose 2

    Combination Product: SP-101 and doxorubicin Cohort 2

  • Experimental
    Dose Expansion

    Single inhalational administration of SP-101 and doxorubicin Selected Dose

    Combination Product: SP-101 and doxorubicin Cohort 1 · Combination Product: SP-101 and doxorubicin Cohort 2

Interventions

  • Combination productSP-101 and doxorubicin Cohort 1

    Drug page: Doxorubicin

    Single inhaled dose of SP-101 and doxorubicin Dose 1

    Also known as: SP-101, doxorubicin

  • Combination productSP-101 and doxorubicin Cohort 2

    Drug page: Doxorubicin

    Single inhaled dose of SP-101 and doxorubicin Dose 2

    Also known as: SP-101, doxorubicin

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Safety and tolerability of SP-101 following a single inhalation dose, as assessed by incidence and severity of treatment emergent adverse events, serious adverse events, and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters.

    Time frame: 52 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Excoffon KJDA, Smith MD, Falese L, Schulingkamp R, Lin S, Mahankali M, Narayan PKL, Glatfelter MR, Limberis MP, Yuen E, Kolbeck R. Inhalation of SP-101 Followed by Inhaled Doxorubicin Results in Robust and Durable hCFTRDeltaR Transgene Expression in the Airways of Wild-Type and Cystic Fibrosis Ferrets. Hum Gene Ther. 2024 Sep;35(17-18):710-725. doi: 10.1089/hum.2024.064. Epub 2024 Sep 4. PubMed 39155828 ↗
  • Excoffon KJDA, Lin S, Narayan PKL, Sitaraman S, Jimah AM, Fallon TT, James ML, Glatfelter MR, Limberis MP, Smith MD, Guffanti G, Kolbeck R. SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia From Donors with Cystic Fibrosis. Hum Gene Ther. 2024 Sep;35(17-18):695-709. doi: 10.1089/hum.2024.063. Epub 2024 Aug 29. PubMed 39155805 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 30, 2024
StartActual
Sep 16, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06526923
Lead sponsor
Spirovant Sciences, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Sep 16, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 25, 2024

Study contacts

Spirovant.ClinicalTrials
Contact
clinicaltrials@spirovant.com
(267) 805-6747
Jessica Lee, MPH
study director · Spirovant Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion